Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | NPY1R | P25929 | 1/20 | 0.61 |
| ▸ | NPY2R | P49146 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831331 | 0.88 | CFTR (0.57) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL6108626 | 0.88 | KDM4E (0.68) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL4800345 | 0.85 | KDM4E (0.59) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL4836211 | 0.84 | MAPT (0.54) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL7303802 | 0.83 | NR1H4 (0.62) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL5223816 | 0.82 | NR1H4 (0.65) | MAPTSMN1; SMN2RAB9APOLBNR1H4 | |
| SCHEMBL4830861 | 0.82 | CFTR (0.52) | KDM4EMAPTGAAMAPK1CYP1A2 | |
| SCHEMBL11500979 | 0.81 | MAPT (0.68) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL7302258 | 0.81 | HPGD (0.64) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL6108092 | 0.81 | TSHR (0.72) | KDM4EALDH1A1HPGDMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-7420083-B2 | Substituted aryloximes | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7342039-B2 | Substituted indole oximes | WYETH (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1667670-A1 | 4-(1H-INDOL-3-YL-METHYLIDENEAMINOXY-PROPOXY)-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1667676-A1 | 4-(1-BENZOFURAN-3-YL-METHYLIDENEAMINOXY-PROPOXY)-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1663189-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050215626-A1 | Substituted benzofuran oximes; inhibiting PAI-1 activity; Plasminogen Activator Inhibitor (PAI); treating thrombosis, pulmonary fibrosis, stroke, myocardial ischemia, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, Alzheimer's disease, renal fibrosis, or cancer | WYETH (US) | 2005-09-29 | — | — | US | disclosed |
| US-20050119326-A1 | Substituted aryloximes | WYETH (US) | 2005-06-02 | — | — | US | disclosed |
| WO-2005030199-A1 | 4-(1-BENZOFURAN-3-YL-METHYLIDENEAMINOXY.PROPOXY))-BENZOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030193-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030192-A1 | 4- (1H-INDOL-3-YL-METHYLIDENEAMINOXY-PROPOXY) -BENZIOC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070584-A1 | Substituted aryloximes | WYETH (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070584-A1 | Substituted aryloximes | AHR, NQO1, AOX1 | KDM4E 509/4885ALDH1A1 269/4885HPGD 383/4885 |
| US-20050215626-A1 | Substituted benzofuran oximes; inhibiting PAI-1 activity; Plasminogen Activator Inhibitor (PAI); treating thrombosis, pulmonary fibrosis, stroke, myocardial ischemia, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, Alzheimer's disease, renal fibrosis, or cancer | SERPINE1, PLAT, SERPINB1 | KDM4E 2211/4885ALDH1A1 330/4885HPGD 380/4885 |
| US-20050119326-A1 | Substituted aryloximes | IDO2, TDO2, IDO1 | KDM4E 594/4885ALDH1A1 304/4885HPGD 364/4885 |
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | HCCS, AOX1, TET2 | KDM4E 598/4885ALDH1A1 211/4885HPGD 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.